Related Experiment Videos
Cost-effective management of chronic stable angina
1University of Texas Health Science Center at San Antonio 8284-7872, USA.
Insights
For stable angina, treatment choice depends on patient risk. High-risk patients may benefit from coronary bypass surgery (CABG) or angioplasty, while low-risk patients often receive medical therapy.
Area of Science:
- Cardiology
- Interventional Cardiology
- Preventive Cardiology
Background:
- Stable angina management involves surgical revascularization (coronary bypass surgery or angioplasty) or anti-ischemic drug therapy.
- Patient risk stratification is crucial, considering coronary disease extent, symptoms, ischemia severity, and left ventricular function.
Purpose of the Study:
- To outline therapeutic options for stable angina based on patient risk stratification.
- To analyze the cost-effectiveness of different treatment strategies for coronary artery disease.
Main Methods:
- Review of clinical characteristics to categorize patients into low-, moderate-, and high-risk groups.
- Evaluation of cost-effectiveness data for medical therapy, coronary angioplasty, and coronary bypass surgery (CABG).
Main Results:
- High-risk patients, especially those with triple-vessel disease and impaired left ventricular function, often benefit from CABG.
- Coronary angioplasty is cost-effective for patients with severe angina and single- or multivessel disease.
- Medical therapy or angioplasty are preferred initial strategies for low-risk coronary disease.
Conclusions:
- Treatment decisions for stable angina should be individualized based on risk stratification and cost-effectiveness.
- Coronary bypass surgery (CABG) is recommended for specific high-risk patient profiles.
- Anti-ischemic drug therapy and secondary prevention offer good long-term prognosis for selected patients.
Abstract:
In certain patients with stable angina who are at moderate to high risk, coronary bypass surgery or coronary angioplasty are the therapeutic options of choice. However, in selected other patients the use of anti-ischemic drug therapy and secondary prevention reduce episodes of myocardial ischemia and result in a good long-term prognosis. Factors affecting management include the extent of coronary disease, the magnitude of cardiac symptoms, the severity of myocardial ischemia and of left ventricular function. Based upon these and other clinical characteristics, patients can be divided into low-, moderate-, or high-risk categories for morbidity and mortality. Patients at high risk are more likely to be selected for myocardial revascularization and patients at low risk are often treated with medical therapy, at least initially. Based on the available cost-effectiveness data, medical therapy or coronary angioplasty are the preferred initial strategies for low-risk coronary disease, whereas coronary bypass surgery (CABG) is recommended for many high-risk patients, particularly for those with triple-vessel disease and impaired left ventricular function or ischemia at a low workload. CABG is cost-effective for patients with severe angina and left main coronary artery disease and also for patients with mild angina and triple-vessel disease. Coronary angioplasty is cost-effective for patients with severe angina, and single- or multivessel disease. In patients with lesser symptoms and mild coronary disease, the cost effectiveness of myocardial revascularization therapy is less likely to be as good as it is in patients with more extensive disease and severe symptoms.